

# AsiaTIDES: Oligonucleotide & Peptide Therapeutics

February 27-March 1, 2018  
Westin Miyako Kyoto  
Kyoto, Japan

**THE ONLY EVENT IN ASIA BRINGING TOGETHER  
SCIENCE, TECHNOLOGIES AND PARTNERS TO  
ACCELERATE OLIGONUCLEOTIDE AND PEPTIDE  
MOLECULES TO MARKET**

## Keynote Presentations



Transforming Daiichi Sankyo into a Global Pharma Innovator: Updated Directions and Future Vision of R&D

**Junichi Koga, Ph.D.**

Head of R&D Division, Executive Officer, Daiichi Sankyo, *Japan*



Recent Progress in the Discovery and Development of Macrocyclic Peptides

**Patrick Reid, Ph.D.**

Chief Scientific Officer, PeptiDream, Inc., *Japan*



Delivering Biopharmaceuticals across Biobarriers: Opportunities and Challenges in Drug Development

**Ekkehard Leberer, Ph.D.**

Senior Director, R&D Alliance Management, Sanofi and Scientific Managing Director, COMPACT Consortium, Innovative Medicine Initiative, *Germany*



Stunning Clinical Effectiveness of RNA/ENA Chimera Antisense Oligonucleotide (A085) against Dystrophin Exon 45 in DMD Patient

**Yasuhiro Takeshima, M.D., Ph.D.**

Professor, Department of Pediatrics, Hyogo College of Medicine, *Japan*

**Register by 8 December and Receive a \$300 USD Savings**

**[www.AsiaTIDSEvent.com](http://www.AsiaTIDSEvent.com)**

# APPLY THE LATEST INNOVATIONS IN OLIGONUCLEOTIDE AND PEPTIDE DEVELOPMENT



## ACCELERATE YOUR PRODUCT TO MARKET



Hear case studies, best practices and lessons learned from global oligonucleotide and peptide developers currently in preclinical and phase 1/2/3 clinical trials. Ensure product approval by hearing regulatory guidance and roadmaps to successful IND/IMPd submissions from industry leaders.

## MEET YOUR NEXT PARTNER AT ASIATIDES



Connect with 300+ oligonucleotide and peptide leaders across Asia, Europe and North America during networking lunches, poster sessions, dinners and cocktail receptions.

## EVALUATE NEW TECHNOLOGIES AND SERVICES



Improve your discovery, clinical, process development, analytical and manufacturing efforts by meeting with 20+ global technology leaders in the exhibit hall. The exhibit hall also features peer-submitted posters that contain new and unpublished research from global scientists working across all phases of oligonucleotide and peptide development.



**Workshop #1:  
Accelerating Oligonucleotides to  
IND and Beyond**

*Workshop Moderator:*

**Marc M. Lemaître, Ph.D.**, Principal, **ML Consult, USA**

*Speakers:*

**Making Drugs out of Oligonucleotides: Role of Chemical Modifications**

**Muthiah (Mano) Manoharan, Ph.D.**, Senior Vice President of Drug Discovery, **Alnylam Pharmaceuticals, USA**

**Process Development and Early Stage Development—Lessons Learned from a Few Cases Studies**

Companies moving to clinic for the first time with oligonucleotides usually face a lot of questions. In this presentation, we will address those questions with respect to the CMC parts of an IND/IMPD for drug substance and drug product, based on recent experiences.

**Marc M. Lemaître, Ph.D.**, Principal, **ML Consult, USA**

**Regulatory Considerations for Oligonucleotide Therapeutics**

**David T. Lin, Ph.D.**, Senior Consultant, **Biologics Consulting**, (and Former Chemistry Reviewer, **CDER, FDA**), **USA**

**Delivery Strategies for Oligonucleotides**

**Speaker TBA**

**Workshop #2:  
An Introduction to Peptide Therapeutic  
Development: Strategies for Moving to  
the Clinic, CMC and Beyond**

*Workshop Moderators:*

**Christopher A. Rhodes, Ph.D.**, *President & CEO, Drug Delivery Experts, USA*

**Bruce H. Morimoto, Ph.D.**, *Vice President, Scientific Affairs, Celerion, USA*

*Speakers:*

**Regulatory Considerations for Peptide Therapeutics**

**Duu-Gong Wu, Ph.D.**, Senior Director, Regulatory Consulting, **PPD** (and Former Deputy Division Director of Division of New Drug Chemistry, **CDER, FDA**), **USA**

**Formulation Considerations for Peptide Therapeutics**

**Christopher A. Rhodes, Ph.D.**, *President and CEO, Drug Delivery Experts, USA*

**Bioanalytical Strategies for Peptides**

**Rafiq Islam**, Senior Director, Bioanalytical Services, **Celerion, USA**

**Analytical Characterization of Peptides**

**Speaker TBA**



**MAIN CONFERENCE • PLENARY KEYNOTE SESSION • TUESDAY, FEBRUARY 27, 2018**

1:55 **Chairperson's Remarks**

**Osamu Sam Sato, Ph.D.**, Executive Director, R&D Planning Department, **Daiichi Sankyo Co., Ltd., Japan**

2:00 **Transforming Daiichi Sankyo into a Global Pharma Innovator: Updated Directions and Future Vision of R&D**

**Junichi Koga, Ph.D.**, Head of R&D Division, Executive Officer, **Daiichi Sankyo, Japan**



2:35 **Recent Progress in the Discovery and Development of Macrocyclic Peptides**

PeptiDream will present some of its recent progress in the discovery and development of therapeutics arising from its PDPS technology. PDPS technology has proven to be a powerful hit finding platform effective against almost any target. PeptiDream has evolved to turn those initial constrained peptide hit candidates into peptide therapeutics, small molecule therapeutics, and peptide-drug conjugates.

**Patrick Reid, Ph.D.**, Chief Scientific Officer, **PeptiDream, Inc., Japan**



3:10 **Networking Refreshment Break**

3:40 **Stunning Clinical Effectiveness of RNA/ENA Chimera Antisense Oligonucleotide (AO85) against Dystrophin Exon 45 in DMD Patient**

A modified nucleotide of 2'-O, 4'-C-ethylene-bridged nucleic acid (ENA) has been shown to have high binding affinity for the complementary RNA strand and nuclease resistance. We have identified an 18-mer antisense RNA/ENA chimera against dystrophin exon 45 (AO85) that is able to induce skipping of dystrophin exon 45. Here, we report the clinical effectiveness of AO85 which was administered intravenously in DMD patient.

**Yasuhiro Takeshima, M.D., Ph.D.**, Professor, Department of Pediatrics, **Hyogo College of Medicine, Japan**



4:15 **Delivering Oligonucleotides, Peptides and Other Biopharmaceuticals across Biobarriers: Opportunities and Challenges in Drug Development**

**Ekkehard Leberer, Ph.D.**, Senior Director, R&D Alliance Management, Sanofi and Scientific Managing Director, **COMPACT Consortium, Innovative Medicine Initiative, Germany**



4:50 **Close of Day One**

5:30 **Networking Dinner in Kyoto**

Join fellow attendees in a fantastic networking and dining opportunity at a local restaurant in beautiful Kyoto. Space is limited and an additional fee applies. Please indicate when you register if you plan to join the dinner.



# MAIN CONFERENCE • PLENARY SESSION • WEDNESDAY, FEBRUARY 28, 2018

8:00 *Registration and Coffee*

## Regulatory Strategies for Oligonucleotide and Peptides

8:55 **Chairperson's Remarks**

9:00 **Regulatory Considerations for the Development of Oligonucleotide Therapeutics in the United States**

The typical factors for development of oligonucleotide products include potency/efficacy, stability in vivo, favorable pharmacokinetics (PK), favorable pharmacodynamics (PD), minimization of off-target effects and safety. However, oligonucleotide drugs fall somewhere between small molecules and large-molecule biologics, creating a new set of unique regulatory challenges. Oligonucleotides are chemically synthesized, and despite the diversity within this class of drugs, there are similarities in approaches for synthesis. This presentation will focus on quality expectations for oligonucleotide products and will explore the application of the quality concerns to oligonucleotide products.

**David T. Lin, Ph.D.**, Senior Consultant, **Biologics Consulting** (and Former Chemistry Reviewer, **CDER, FDA**), USA

9:30 **Regulatory Issues and Challenges during Different Phases of Peptide Product Development in US**

Peptides as chemically-synthesized molecules with biological activities present some unique regulatory challenges during the product development. For peptide products, the approvals for marketing as both drugs and biologics under different laws and regulations and review organizations with US FDA add additional complexities and difficulties during different phases of development in United States. The presentation will discuss: 1) Current regulatory trend in US for the review and approval of peptide products, 2) Different regulatory issues and data requirements for the peptide products to be developed as a drug or biologic and 3) How to navigate the unique regulatory and scientific issues during different phases of peptide development, e.g. to avoid clinical hold.

**Duu-Gong Wu, Ph.D.** Senior Director, **Regulatory Consulting, PPD** (and Former Deputy Division Director of Division of New Drug Chemistry, **CDER, FDA**), USA

10:00 **Novel siRNA Therapeutics for Fibrotic Disease Treatment with Polypeptide Nanoparticle Delivery Technology: Regulatory Experiences in US and China**

Using a proprietary and optimized polypeptide-based delivery technology, we have developed the novel antifibrotic therapeutics with siRNAs targeting both TGF $\beta$ 1 and Cox-2 simultaneously, for initial indication of skin hypertrophic scar followed with liver fibrosis and other fibrotic conditions. With IND approvals by both US FDA and China CFDA, we have started clinical phase 2a in US and preparing clinical phase 1 in China for our leading drug candidate STP705 (Cotsiranib®) to treat human skin hypertrophic scar. I will discuss the unique advantage of our Polypeptide Nanoparticle (PNP) technology platform for safe and efficient siRNA delivery, and our strategy for advancing multiple clinical studies in both China and USA in near future.

**Patrick Y. Lu, Ph.D.**, President & CEO, **Nanotides Pharmaceuticals, Inc.**, USA

10:30 *Networking Refreshment Break with Exhibit and Poster Viewing*

# MAIN CONFERENCE • CONCURRENT TRACKS • WEDNESDAY, FEBRUARY 28, 2018

## OLIGONUCLEOTIDE TRACK

### Preclinical and Clinical Updates

11:10 **Chairperson's Remarks**

**William Marshall, Ph.D.**, President & CEO, **miRagen Therapeutics, Inc.**, USA

11:15 **Non-clinical Development of DCR-PHXC for the Treatment of Primary Hyperoxalurias**

Primary hyperoxalurias are closely related genetic disorders resulting in elevated oxalate production in the liver. Excess oxalate accumulates in the urine where it often precipitates with calcium, leading to a variety of symptoms including frequent and severe kidney stone formation, nephrocalcinosis, and kidney failure. We are investigating a potential treatment for all forms of primary hyperoxaluria with a GalNAc-conjugated Dicer-substrate siRNA targeting the enzyme LDHA.

**Bob D. Brown, Ph.D.**, CSO, SVP Research and Development, **Dicerna Pharmaceuticals, Inc.**, USA

11:45 **Discovery and Development of microRNA Targeting Therapeutic Candidates for the Treatment of Hematological Malignancy and Pathological Fibrosis**

MicroRNAs regulate the expression of gene networks that culminate in the control of complex cellular processes. Dysregulation of the expression of certain microRNAs may affect pathways that contribute to disease pathology. We have advanced two product candidates into clinical trials; MRG-106, a LNA anti-miR® targeting microRNA-155 in hematological malignancies and MRG-201, a synthetic replacement (promiR) for microRNA-29 in pathological fibrosis. An overview of our latest clinical observations will be presented.

**William Marshall, Ph.D.**, President & CEO, **miRagen Therapeutics, Inc.**, USA

12:15 **GalNAc Conjugates for the Advancement of RNAi Therapeutics**

GalNAc Conjugates have revolutionized the field of RNAi therapeutics. Alnylam has advanced many therapeutic programs using this platform technology. The challenges, solutions and human therapeutic applications of GalNAc conjugated siRNAs will be presented.

**Muthiah (Mano) Manoharan, Ph.D.**, Senior Vice President of Drug Discovery, **Alnylam Pharmaceuticals**, USA

12:45 *Networking Luncheon with Exhibit and Poster Viewing*

## PEPTIDE TRACK

### Peptide Discovery and Development

11:10 **Chairperson's Remarks**

11:15 **Genetically-Encoded Chemically-Modified Peptides**

We use genetically-encoded (GE) libraries as starting materials for multi-step organic synthesis. Examples are N-terminal conjugation<sup>1</sup> and cyclization of linear peptides<sup>2</sup> with simultaneous introduction of glycan entities. We developed the Genetically-Encoded Fragment-Based Discovery (GE-FBD) platform;<sup>3</sup> which combines >109 peptides with GE-modifications.<sup>4</sup> The talk will describe the progress and challenges in application of GE-FBD platform.

References:

1. (a) J. Am. Chem. Soc., 2014, 136, 8149. (b) ACS Chem. Biol., 2012, 7, 1482
2. (a) Chem. Sci., 2016, 7, 3785. (b) Org. Biomol. Chem., 2016, 14, 5539-5545.
3. Ng et al., J. Am. Chem. Soc., 2015, 137, 5248
4. Tjhung et al., J. Am. Chem. Soc., 2016, 138, 32.

**Ratmir Derda, Ph.D.**, Associate Professor, Department of Chemistry, **University of Alberta**, Canada

11:45 **Discovery and Development of Synthetic Polymyxins for Targeting Gram-negative 'Superbugs'**

In this presentation, we report on our ongoing pre-clinical polymyxin drug development program, a National Institutes of Health (NIH) funded joint academic-industry collaboration between Monash University (Australia) and The Medicines Company (USA). This program aims to produce new polymyxin peptide clinical candidates with improved safety and efficacy over the currently used drugs, polymyxin B and colistin. Aspects of our novel drug design strategy and lead optimization studies will be discussed. To date a number of promising lead candidates have been identified with significantly improved safety profiles and are being progressed towards clinical evaluation.

**Kade Roberts, Ph.D.**, Senior Research Fellow, Biomedicine Discovery Institute, **Monash University**, Australia

12:15 **Polypharmacy through Phage Display: Selection of Glucagon and GLP-1 Receptor Co-agonists from a Phage-Displayed Peptide Library**

An emerging area for the treatment of obesity and diabetes is combinatorial hormone therapies, where single molecule peptides are rationally designed to integrate the complementary actions of multiple endogenous metabolically-related hormones. In this study, we report unimolecular polypharmacy agents selected on phage-displayed peptide libraries (PDL). Co-agonists of the glucagon (GCG) and GLP-1 receptors were identified after sequentially selection on GCGR- and GLP1R-overexpressing cells, showing EC<sub>50</sub> ≤ 30 pM on each receptor. These results validate the approach for the discovery of optimized polypharmacology paradigms across several metabolically-related hormones.

**Elisabetta Bianchi**, Head of Peptide Chemistry, **IRBM Science Park**, Italy

12:45 *Networking Luncheon with Exhibit and Poster Viewing*

**OLIGONUCLEOTIDE TRACK**

**Preclinical and Clinical Updates (continued)**

- 1:55 **Chairperson's Remarks**  
William Marshall, Ph.D., President & CEO, **miRagen Therapeutics, Inc., USA**
- 2:00 **Clinical Update on DS-5141b an Oligonucleotide Drug for DMD Treatment**  
Osamu Sam Sato, Ph.D., Executive Director, R&D Planning Department, **Daiichi Sankyo Co., Ltd., Japan**
- 2:30 **An Oligonucleotide for the Treatment of Duchenne Muscular Dystrophy (DMD): An Update after Launch**  
Speaker TBA, **Sarepta Therapeutics, USA**

**Manufacturing, CMC and Purification Strategies**

- 3:00 **New Developments in Oligonucleotide Manufacturing and CMC Strategy**  
Alun Garner, Business Development Manager, Nucleic Acid Solutions Division, **Agilent Technologies, Inc., USA**
- 3:30 **Networking Refreshment Break with Exhibit and Poster Viewing**
- 4:00 **5'-GalNAc-Conjugated Antisense Oligonucleotides: Synthesis and Purification Challenges**  
GalNAc-conjugated oligonucleotides represent an exciting approach to antisense therapy. In this presentation, we will discuss the challenges associated with production of these compounds. Solution-phase and solid-phase conjugation strategies capable of generating high-quality product will be presented and compared in terms of yield and purity.  
Andrew Rodriguez, Ph.D., Assistant Director, Process Chemistry, **Ionis Pharmaceuticals, USA**
- 4:30 **New Purification Process for Antisense Oligonucleotides**  
Recent efforts in oligonucleotide purification development have shown that an all aqueous process can achieve higher purities by employing orthogonal separation mechanisms. Higher purity is obtained by reducing challenging impurities such as N-1, P=O, N+1, without sacrificing yield. Positioning the detritylation step between the columns provides robust reaction control. An example of this process and its capabilities will be presented.  
Robert S. Gronke, Ph.D., Senior Principal Scientist, Technical Development, **Biogen, USA**
- 5:00 **Networking Cocktail Reception in the Exhibit and Poster**
- 6:00 **Close of Day Two**

**Meet the AsiaTIDES 2018 Scientific Advisory Board**



- Hiroaki Suga, Ph.D.**, Professor of Chemistry, School of Science, **University of Tokyo, Japan**
- Osamu Sato**, Executive Director, R&D Planning Department, **Daiichi Sankyo, Japan**
- Daisuke Takahashi, Ph.D.**, Manager, Bio-functional Molecular Chemistry Group, Research Institute for Bioscience Products & Fine Chemicals, **Ajinomoto Co., Inc., Japan**
- Hideaki Sato**, General Manager, Technical Support and Marketing, **GeneDesign, Inc., Japan**
- Robert Hagopian**, Director Business Development, **PolyPeptide Laboratories, USA**
- Yasuhiro Hayashi, Ph.D.**, Chief Scientist, Drug Discovery Group, R&D Division, **AnGes MG, Inc., Japan**
- Yusuke Kohno**, Vice President, **Jitsubo Co Limited, Japan**
- Dong-ki Lee, Ph.D.**, Professor, Sungkyunkwan University and CEO & Founder, **OliX Pharmaceuticals, Korea**
- Shawn Lee, Ph.D.**, President and CEO, CPC Scientific, **USA and China**
- Patrick Lu, Ph.D.**, Founder, President and CEO, **Sirnaomics, Inc., USA**
- Michael McGinley**, Manager- Core Products, **Phenomenex, USA**
- Bruce Morimoto, Ph.D.**, Executive Director Applied Translational Medicine, **Celerion, USA**
- El Djouhar Rekaï**, Head of Peptide Products Operation, **PolyPeptide Group, Belgium**
- G. Susan Srivatsa, Ph.D.**, President, **ElixinPharma, USA**
- Dmitry Samarsky, Ph.D.**, Chief Scientific Officer, **Silence Therapeutics, USA**
- Mimoun Ayoub, Ph.D.**, Industry Expert

**PEPTIDE TRACK**

**Peptide Discovery and Development (continued)**

- 1:55 **Chairperson's Remarks**
- 2:00 **Intracellular Screening for Specific Peptide Antagonists of Proteins**  
We use Protein-fragment Complementation to identify peptide antagonists of therapeutically relevant targets that include the oncogenic Activator Protein-1 transcriptional regulator, and  $\beta$ -amyloid /  $\alpha$ -synuclein proteins implicated in AD/PD. Target-specificity is increased by expressing off-target proteins during selection. Antagonists are downsized and refined using structure-inducing constraints and non-natural sequences.  
Jody Mason, Ph.D., Senior Lecturer in Biochemistry, **University of Bath, United Kingdom**
- 2:30 **I/O, CBP501 Combo Clinical Trial: Rationale and Updates**  
Update on CBP501, a 12aa d-type peptide. It binds calmodulin, increases cytotoxicity of platinum, induces tumor immunogenic cell death, suppresses M2 macrophages, reduces cancer stem cells, and suppresses epithelial-to-mesenchymal transition. A Phase Ib study for the triple drug combination of CBP501, cisplatin and anti-PD1 antibody is ongoing.  
Takumi Kawabe, M.D., Ph.D., President & CEO, **CanBas Co., Ltd., Japan**

**Control Strategies for Peptide Impurities and Peptide Manufacturing Learnings**

- 3:00 **Oral Peptide Development/CMC: Learnings from Scaling up API and Reducing Costs for Peptide Manufacturing**  
Major consumable costs for peptide manufacturing include the cost of protected amino acids, coupling reagents, and solvents. At smaller scales, labor and manufacturing facility expenses dominate manufacturing cost. However, at larger scales acquisition and disposition of solvents dominate cost. The relative costs and advantages of solid phase, solution phase and hybrid solid/solution phase manufacturing of peptides for oral use will be discussed.  
Robert Geiger, Ph.D., Vice President of QA and Generic APIs, **AmbioPharm, USA**
- 3:30 **Networking Refreshment Break with Exhibit and Poster Viewing**
- 4:00 **Higher Molecular Weight (HMW) Peptide Impurities – Control Strategies and Acceptance Criteria**  
  
For peptide drug substances in early clinical development there is often a very strong focus on fast drug substance supply. Therefore, the development of manufacturing process capabilities and economy as well as purity and impurity profile is performed in parallel. Aggregation-prone peptides implicate additional challenges for process development. Furthermore, it is known that sometimes sub-optimal quality attributes such as poor solubility, a shortened shelf life due to high HMW-content may only become apparent in subsequent drug product formulations. Different methods and strategies are applied at BACHEM to minimize and control HMW species of aggregation-prone peptides during synthetic downstream processing. Focusing on typical process stages, BACHEM's standard approach for optimization of process parameters regarding aggregation is presented within different case studies.  
Daniel Samson, Ph.D., Vice President API SPPS, **Bachem AG, Switzerland**
- 4:30 **Control of Non-Peptide Impurities in APIs Originated from Materials/ Consumables/Equipment Contact through Process Manufacturing and Storage**  
  
Pharmaceutical industries devote significant efforts to identify, quantify, and minimize level of impurities in drug products and consequently in drug substances (APIs). Chemical compounds can be leached into API from various components used in the manufacturing processes leading to potential adulteration of the API, and potentially affecting safety or efficacy of the drug product. This concern drives manufacturers to develop relevant control strategies. This presentation gives an overview and background of our risk management approach to address extractables / leachables, including elemental impurities, in peptide APIs.  
El Djouhar Rekaï, Ph.D., Head of Products Operation, **PolyPeptide Group, Belgium**
- 5:00 **Networking Cocktail Reception in the Exhibit and Poster**
- 6:00 **Close of Day Two**

# MAIN CONFERENCE • PLENARY SESSION • THURSDAY, MARCH 1, 2018

8:00 *Registration and Coffee*

## Delivery and Targeting Strategies

8:40 **Chairperson's Remarks**

8:45 **LNP: Delivering mRNA Therapeutics to the Clinic**

Arbutus' Lipid Nanoparticle (LNP) platform is enabling several early and late stage clinical trials. They are designed to deliver their nucleic acid payloads to sites of disease and have been used to target both viral and endogenous gene targets. Here we describe their application to mRNA payloads.

**James Heyes, Ph.D.**, Vice President, Drug Delivery, **Arbutus Biopharma, Corp.**, Canada

9:15 **Arrowhead's TRM™ Delivery System – Potent, Modular and Versatile for RNAi**

Arrowhead's new TRM™ delivery system is designed for RNAi trigger delivery to a variety of tissues, not just the liver. We expect to be in human trials with this new technology in 2018 as we look to expand the boundaries of current RNAi efforts.

**Bruce D. Given, M.D.**, Chief Operating Officer, **Arrowhead Pharmaceuticals, Inc.**, USA

9:45 **Enhancing ASO Activity in Extra-Hepatic Tissues**

**Punit Seth, Ph.D.**, Vice President, Medicinal Chemistry, **Ionis Pharmaceuticals**, US

10:15 *Networking Refreshment Break with Exhibit and Poster Viewing*

# MAIN CONFERENCE • CONCURRENT TRACKS • THURSDAY, MARCH 1, 2018

## OLIGONUCLEOTIDE TRACK

### Oligonucleotide Case Studies

10:55 **Chairperson's Remarks**

11:00 **Advancing LNA Therapeutics**

Recently therapeutic oligonucleotide discovery has seen a shift from paradigms based primarily upon sequence diversity, towards exploiting both sequence and design diversity: Small structural alterations can greatly affect the pharmacological properties of oligonucleotides. More recently, it has been realized that the specific stereo definition of phosphorothioate internucleoside linkages (PS) in LNA oligonucleotides are also strong pharmacological determinants. It will be shown in the presentation that new opportunities for oligonucleotide drug discovery are enabled when collective sets of diversity parameters are exploited.

**Troels Koch, Ph.D.**, VP & Head of Research, RNA Therapeutics, **Roche Innovation Center, Copenhagen**, Denmark

11:30 **Use of Advanced siRNAs Targeted to Hepatocytes for the Development of Novel Drugs to Treat Liver-related Disorders**

Conjugation of the N-acetylgalactosamine (GalNAc) moieties to the siRNAs allows precise and highly effective knockdown of various genes in the liver, specifically in hepatocytes, of the vertebrate organisms. We will describe how Silence Therapeutics develops novel therapeutic programs addressing hepatocyte-associated diseases using its proprietary GalNAc-siRNA technology.

**Dmitry Samarsky, Ph.D.**, Chief Scientific Officer, **Silence Therapeutics**, Germany

12:00 **Asymmetric siRNA Targeting Fibrotic Disorders**

**Dong-ki Lee, Ph.D.**, Professor, **Sungkyunkwan University** and Founder and CEO, **OliX Pharmaceuticals**, Korea

12:30 *Networking Luncheon with Exhibit and Poster Viewing*

1:40 **Chairperson's Remarks**

1:45 **Pushing RNA Targeting Drug Development in China towards Clinical Stages**

Over the years we have established a comprehensive platform for siRNA drug development in Kunshan, China and through our intramural research and high end collaborations with world leaders in the sector such as Ionis and Quark, we have been able to not only add the antisense dimension to our drug pipeline, but also push the first siRNA drug into the clinical stage. This combinatoric strategy will allow us to advance 3-4 RNA targeting drugs into IND or clinical stages over the next 12-18 months.

**Zicai Liang**, Chairman and CEO, **Suzhou Ribo Life Science Co. Ltd.**, China

2:15 **Recent Advances in RNAi Therapeutics at Arrowhead Pharmaceuticals**

In the presentation, Arrowhead Pharmaceutical's new hepatic delivery platform TRiM will be presented. Recent in vivo data in rodents and NHP for ARO-AAT and ARO-HBV will be discussed. ARO-AAT is for the treatment for a genetic disorder, alpha-1 antitrypsin deficiency (AATD), and ARO-HBV is for the treatment of hepatitis B. DMPC data in these two programs will also be disclosed.

**Zhen Li, Ph.D.**, Vice President, Chemistry and Manufacturing, **Arrowhead Pharmaceuticals**, USA

### Oligonucleotide CMC Strategies

2:45 **AJIPHASE® Process Development Focusing on Impurity Suppression**

To address the rising demand of oligonucleotide drugs, we have been developing a unique and novel solution-phase synthesis, AJIPHASE®. The significant difference between AJIPHASE® technology and solid-phase synthesis is that our technology can show the reaction detail in each step by direct analysis. This presentation will highlight the elucidation of side reaction in AJIPHASE® and suppression of the impurities to obtain high purity oligonucleotides.

**Taisuke Ichimaru**, Researcher, Bio-functional Molecular Chemistry Group, **Ajinomoto Co. Inc.**, Japan

3:15 *Networking Refreshment Break with Exhibit and Poster Viewing*

## PEPTIDE TRACK

### Peptide Delivery and Novel Peptide Applications

10:55 **Chairperson's Remarks**

**Bruce H. Morimoto, Ph.D.**, Vice President, Scientific Affairs, **Celerion**, USA

11:00 **Development of Cancer Peptide Vaccines: Can Cancer Peptide Vaccines Survive?**

**Yasuhide Uejima, Ph.D.**, General Manager, CMC & QA, **BrightPath Biotherapeutics, Co., Ltd.**, Japan

11:30 **Exploring Stapled Peptide Permeability Using p53 As a Model System**

Stapled peptides can inhibit intracellular protein-protein interactions to address "yet-to-be-drugged" therapeutic targets. However, their pipeline advancement is hindered by suboptimal membrane permeability. Using cell-active sequences derived from p53, we have generated a library of several hundred stapled peptides to understand how peptide properties dictate membrane permeability. We will describe insights gained and novel screening tools.

**Anthony Partridge, Ph.D.**, Principal Scientist, Early Discovery Pharmacology, Translational Medicine Research Centre, **Merck Sharp & Dohme**, Singapore

12:00 **Applications of Biodegradable Silica in Parenteral Delivery of Peptides**

Biodegradable silica polymer matrix provides a versatile tool for controlled release of parenteral therapeutics. Peptides and proteins are easily and effectively encapsulated in nanoporous silica using the sol gel process which preserves the biological activity of these molecules. Because the drug release is based on adjustable matrix surface erosion, very accurate zero-order release profiles can be obtained. Using this technology, it is possible to administer peptides in a controlled manner even for several months.

**Lasse Leino, Ph.D.**, Adjunct Professor and CEO, **DelSiTech Ltd.**, Finland

12:30 *Networking Luncheon with Exhibit and Poster Viewing*

1:40 **Chairperson's Remarks**

**Bruce H. Morimoto, Ph.D.**, Vice President, Scientific Affairs, **Celerion**, USA

1:45 **Update on Advances in Oral Delivery of Peptides**

The various technologies and strategies for oral delivery of peptides will be discussed. In addition, data available from literature examples will be used to provide concrete examples for the pharmacokinetics profile achieved with each technology. Finally, new technologies that show some promise for oral delivery will be discussed.

**Christopher A. Rhodes, Ph.D.**, President & CEO, **Drug Delivery Experts**, USA

2:15 **Functional Peptide-modified Exosomes for Intracellular Delivery of Therapeutic Molecules**

Exosomes are naturally occurring nanomaterials and could potentially represent the next generation of biological tools for delivering therapeutic molecules. However, the low cellular targeting efficacy and insufficient release of exosomal contents inside the cytosol can hinder their application. I will be discussing novel techniques that were developed to effectively target receptors and enhance cytosolic release of exosomal contents via biofunctional peptides that were modified on exosomal membranes.

**Ikuhiko Nakase, Ph.D.**, Special Lecturer (Tenure Track Lecturer), NanoSquare Research Institution, **Osaka Prefecture University**, Japan

2:45 **Peptide Delivery: How Nanosystems Can Help Address Present and Future Challenges**

**Joel Richard, Ph.D.**, Senior Vice President, Peptides Development, General Manager, **OctreoPharm Science GmbH** and Head of Pharm. Dev. Dreux Site, **IPSEN**, France

3:15 *Networking Refreshment Break with Exhibit and Poster Viewing*

## OLIGONUCLEOTIDE TRACK

- 3:45 **Methodologies for Analytical Control of Synthetic Oligonucleotides**  
 Synthetic oligonucleotides hold great potential to serve as therapeutics for the treatment of human diseases. In this presentation, we illustrate how different analytical methodologies can be used to characterize these complex molecules.  
**Fanyu Meng, Ph.D.**, Principal Scientist, Analytical Research and Development, **Merck Research Labs, Merck & Co., Inc., USA**
- 4:15 **Case Story: What Does It Take to Integrate LNA Phosphoramidite Specialty Building Blocks into the Supply Chain?**  
 The chemical complexity of oligonucleotides drug candidates has increased significantly over the past years. This puts a special focus on the quality of the novel starting materials that are chemically complex and are sources of impurities in the final API. In addition, all these factors put extra pressure on the design of a robust supply chain for the novel building blocks spanning from initiation to drug development.  
**Christoph Rosenbohm, Ph.D.**, VP and Head of Discovery Operations, **Roche Innovation Center Copenhagen, Denmark**
- 4:45 *Close of Conference*

## PEPTIDE TRACK

- 3:45 **Presentation Title TBA**  
**Naoki Yamamoto**, Business Development, **3D Matrix, Japan**
- 4:15 **Presentation Title TBA**  
**Mimoun Ayoub, Ph.D.**, Industry Expert
- 4:45 *Close of Conference*

# BECOME A SPONSOR AND EXHIBITOR

**Connect face-to-face** with highly influential scientists, engineers and executives from industry and academia with the budget and authority to recommend, specify and approve the purchase of products and services to accelerate oligonucleotide and peptide research, discovery efforts and clinical and manufacturing programs. Contact us today to learn about the cost-effective ways to drive lead generation and network with key buyers, including:

- Exhibit Booth Packages
- Event Partner Packages
- Scientific Briefing
- Luncheon Briefing
- Executive Breakfast
- Custom Emails
- Private Meeting Space

A wide variety of options are available to help you meet your company objectives before, during and after the conference.

We provide flexible and tailored solutions to optimize your investment. To get involved and begin building your custom sponsorship package today, contact:

**Patrick Shaughnessy, Phone: +1-857-262-5325, E-mail: Patrick.Shaughnessy@knect365.com**

## GOLD SPONSORS



## SILVER SPONSORS



## EXHIBITORS

